Developing first-in-class medicines
Using synthetic lethality strategy, SynRx Therapeutics is developing novel anti-cancer agents. Several first-in-class compounds are currently in preclinical studies.
Professor,Founder and Chairman
Professor, University of Michigan Medical SchoolM.D.,Beijing Medical UniversityPh.D., Kurume University, JapanPublished more than 100 academic papers
NewsFocus on the development of novel drugs targeting the DNA damage repair pathway
8 The Green,Suite A Dover,Delaware 19901.
Copyright © 2022 SynRx Therapeutics,LLC. All Rights Reserved.